About Kamal Al-Daghmi, Director of the “Blood Company”

The previous day, Friday, King Mohammed VI, at the proposal of the High Minister and at the initiative of the Minister of Well being and Social Coverage, appointed Kamal Al-Daghmi to the placement of Director of the Moroccan Company for Blood and its Derivatives.

Kamal Al-Daghmi holds the placement of physician-major colonel, head of the scientific hematology division on the Mohammed V Army Find out about Clinic in Rabat, and a professor of upper training in hematology on the School of Drugs and Pharmacy in Rabat.

Al-Daghmi, who holds a doctorate in medication from the School of Drugs and Pharmacy in Rabat, a specialization degree from Val de Grasse Clinic in scientific hematology, and a college specialization degree in scientific hematology from René Descartes College, Paris 5, in 2019, was once appointed director of the degree and head of the pedagogy unit. And analysis in scientific hematology on the School of Drugs and Pharmacy in Rabat.

In 2018, the Director of the Moroccan Company for Blood and its Derivatives served as Head of the Medical Hematology Division on the Mohammed V Army Find out about Clinic in Rabat. In 2009, he additionally labored as a prominent professor of scientific hematology on the School of Drugs and Pharmacy in Rabat, and an assistant professor of scientific hematology on the identical school in 2004.

It’s value noting that the Moroccan Company for Blood and Blood Derivatives, created via Legislation No. 11.22, was once charged with “enforcing the strategic instructions of state coverage aimed toward making sure the advance of a human blood reserve that meets nationwide wishes, the provision of all blood derivatives in all instances, making sure their protection and high quality, and wearing out the operations of producing, uploading and advertising and marketing by-product drugs.” of blood and wearing out a number of duties, together with contributing to the preparation, implementation, monitoring and analysis of the nationwide coverage associated with blood, amassing complete blood from donors and wearing out its organic rehabilitation and all paintings associated with its preservation, transformation and packaging. The company will even supervise the advance of the nationwide inventory of blood and its derivatives, prepare all paintings associated with its distribution and use, and provide all well being establishments affiliated with the general public or personal sectors, as wanted, with blood, plasma, purple cellular clots, and platelet clots.